Empower Clinics - CEO, Steven McAuley.
CEO, Steven McAuley.
Source: Empower Clinics.
  • Empower’s (EPW) MediSure subsidiary has been awarded a contract with Correctional Service of Canada (CSC)
  • The three-year, C$1.5 million contract involves the provision of diabetes testing solutions to inmates in federal prisons
  • This is the third time that MediSure has won the CSC contract
  • Empower Clinics is an integrated healthcare company
  • Empower (EPW) is up by 20 per cent, trading at $0.06 per share

Empower’s (EPW) MediSure subsidiary has been awarded a contract with Correctional Service of Canada.

MediSure is a medical device company dedicated to bringing value to the high cost of diabetes, both to patients and insurers.

The three-year, C$1.5 million contract involves the provision of diabetes testing solutions to inmates in federal prisons.

This is the third time that MediSure has won the CSC contract as part of a public request-for-proposal tendering process.

Empower views the contract as a catalyst for revenue generation efforts into additional government agencies.

“MediSure Canada continues to perform, delivering results in both sales and launching innovative products,” stated Steven McAuley, Empower’s Chairman and CEO. “It’s an impressive feat when a client as prominent as the Government of Canada is a happy repeat customer of our diabetes testing solutions.”

“Building a government customer base with trust and loyalty towards the MediSure brand is a top priority,” added Mario Cortis, MediSure’s President. “We know repeat customers tend to spend more, are more likely to try our new products, refer new government clients and overall help to improve our profitability over time.”

Empower Clinics is an integrated healthcare company offering clinical services, digital and telemedicine care, and world-class medical diagnostics.

Empower (EPW) is up by 20 per cent, trading at $0.06 per share as of 11:44 am ET.


More From The Market Online

Avicanna launches 10% CBD (THC free) formula in Canada

Avicanna (TSX:AVCN) launches RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.

Theratechnologies phases down preclinical oncology research

Biopharmaceutical company Theratechnologies (TSX:TH) announced it will phase down its preclinical oncology research activities.